Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata

• Published in: International journal of antimicrobial agents Vol. 47; no. 4; pp. 286 - 288
• Main Authors: Sanchis, Marta, Capilla, Javier, Castanheira, Mariana, Martin-Vicente, Adela, Sutton, Deanna A, Fothergill, Annette W, Wiederhold, Nathan P, Guarro, Josep
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2016
• Subjects: Animal model; Animals; Antifungal Agents - pharmacology; Antifungal Agents - therapeutic use; Antifungals; Candida glabrata; Candida glabrata - drug effects; Candidiasis - drug therapy; Colony Count, Microbial; Disease Models, Animal; Epidemiological cut-off value; Fungal infection; Infectious Disease; Kidney - microbiology; Male; Mice; Microbial Sensitivity Tests; Treatment Outcome; Voriconazole; Voriconazole - pharmacology; Voriconazole - therapeutic use; Antifungals; Animal model; Candida glabrata; Epidemiological cut-off value; Fungal infection; Voriconazole
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2015.12.020

Highlights • We evaluated the efficacy of voriconazole (VRC) against 27 Candida glabrata isolates with varying MICs. • We assessed whether VRC in vitro activity is predictive of in vivo efficacy using an immunosuppressed murine model of candidiasis by C. glabrata. • VRC showed efficacy against strains with MICs < 0.25 μg/mL, variable efficacy when MIC = 0.25 μg/mL and no efficacy at MIC ≥ 0.5 μg/mL. • The epidemiological cut-off value for voriconazole against C. glabrata is 0.25 μg/mL; our results showed efficacy at MIC < 0.25 μg/mL.